Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression

Journal of Virology

Volumn 82, Issue 15, 2008, Pages 7745-7751

  Chang, Shin Shin ^a   Lo, You Chang ^a   Chua, Huey Huey ^a   Chiu, Hsin Yi ^a   Tsai, Shu Chun ^a   Chen, Jen Yang ^b   Lo, Kwok Wai ^c   Tsai, Ching Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN P53; SERINE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA BINDING; EPSTEIN BARR VIRUS; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMEDIATE EARLY PROTEIN BZLF1 GENE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; GENETIC COMPLEMENTATION TEST; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASES; HUMANS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 4;

EID: 47749134215     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02717-07     Document Type: Article

References (47)

1. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
2. Casavant, N. C., M. H. Luo, K. Rosenke, T. Winegardner, A. Zurawska, and E. A. Fortunate. 2006. Potential role for p53 in the permissive life cycle of human cytomegalovirus. J. Virol. 80:8390-8401.
3. Chang, L. K., and S. T. Liu. 2000. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res. 28:3918-3925.
4. Chang, Y., C. H. Tung, Y. T. Huang, J. Lu, J. Y. Chen, and C. H. Tsai. 1999. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J. Virol. 73:8857-8866.
5. Chen, J. Y., W. D. Funk, W. E. Wright, J. W. Shay, and J. D. Minna. 1993. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8:2159-2166.
6. Cheung, S. T., D. P. Huang, A. B. Hui, K. W. Lo, C. W. Ko, Y. S. Tsang, N. Wong, B. M. Whitney, and J. C. Lee. 1999. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83: 121-126.
7. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 5:3243-3249.
8. Chien, Y. C., J. Y. Chen, M. Y. Liu, H. I. Yang, M. M. Hsu, C. J. Chen, and C. S. Yang. 2001. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345:1877-1882.
9. Dyson, P. J., and P. J. Farrell. 1985. Chromatin structure of Epstein-Barr virus. J. Gen. Virol. 66:1931-1940.
10. Feng, W. H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:1920-1926.
11. Fortunato, E. A., and D. H. Spector. 1998. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J. Virol. 72:2033-2039.
12. Gruffat, H., E. Manet, and A. Sergeant. 2002. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 3:141-146.
13. Hall, A. H., and K. A. Alexander. 2003. RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77:6066-6069.
14. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
15. Hoffmann, R., D. J. Craik, G. Pierens, R. E. Bolger, and L. Otvos, Jr. 1998. Phosphorylation of the C-terminal sites of human p53 reduces non-sequence-specific DNA binding as modeled with synthetic peptides. Biochemistry 37:13755-13764.
16. Hong, G. K., M. L. Gulley, W. H. Feng, H. J. Delecluse, E. Holley-Guthrie, and S. C. Kenney. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J. Virol. 79:13993-14003.
17. Horikawa-Miura, M., N. Matsuda, M. Yoshida, Y. Okumura, T. Mori, and M. Watanabe. 2007. The greater lethality of UVB radiation to cultured human cells is associated with the specific activation of a DNA damage-independent signaling pathway. Radiat. Res. 167:655-662.
18. Hsu, C. H., M. Hergenhahn, S. E. Chuang, P. Y. Yeh, T. C. Wu, M. Gao, and A. L. Cheng. 2002. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin. Anticancer Res. 22:4065-4071.
19. Hwang, J. K., and C. T. Lin. 1997. Co-localization of endogenous and exogenous p53 proteins in nasopharyngeal carcinoma cells. J. Histochem. Cytochem. 45:991-1003.
20. Inman, G. J., U. K. Binne, G. A. Parker, P. J. Farrell, and M. J. Allday. 2001. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J. Virol. 75: 2400-2410.
21. Ishizuka, T., and M. A. Lazar. 2003. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell. Biol. 23:5122-5131.
22. Jenkins, P. J., U. K. Binne, and P. J. Farrell. 2000. Histone acetylation and reactivation of Epstein-Barr virus from latency. J. Virol. 74:710-720.
23. Kieff, E. R., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2541-2548. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Wiliams & Willkins, Philadelphia, PA.
24. Lagger, G., A. Doetzlhofer, B. Schuettengruber, E. Haidweger, E. Simboeck, J. Tischler, S. Chiocca, G. Suske, H. Rotheneder, E. Wintersberger, and C. Seiser. 2003. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/ CIP1 gene. Mol. Cell. Biol. 23:2669-2679.
25. Lepik, D., I. lives, A. Kristjuhan, T. Maimets, and M. Ustav. 1998. p53 protein is a suppressor of papillomavirus DNA amplificational replication. J. Virol. 72:6822-6831.
26. Masuda, H., C. Miller, H. P. Koeffler, H. Battifora, and M. J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA 84:7716-7719.
27. Mauser, A., S. Saito, E. Appella, C. W. Anderson, W. T. Seaman, and S. Kenney. 2002. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J. Virol. 76:12503-12512.
28. Nasrin, N., K. Taiba, N. Hannan, M. Hannan, and S. al-Sedairy. 1994. A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. Cancer Lett. 82:189-198.
29. Niedobitek, G., A. Agathanggelou, P. Barber, L. A. Smallman, E. L. Jones, and L. S. Young. 1993. p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J. Pathol. 170:457-461.
30. Pampin, M., Y. Simonin, B. Blondel, Y. Percherancier, and M. K. Chelbi-Alix. 2006. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J. Virol. 80:8582-8592.
31. Pauls, E., J. Senserrich, B. Clotet, and J. A. Este. 2006. Inhibition of HIV-1 replication by RNA interference of p53 expression. J. Leukoc. Biol. 80:659-667.
32. Porter, M. J., J. K. Field, J. C. Lee, S. F. Leung, D. Lo, and C. A. Van Hasselt. 1994. Detection of the tumour suppressor gene p53 in nasopharyngeal carcinoma in Hong Kong Chinese. Anticancer Res. 14:1357-1360.
33. Radhakrishnan, S. K., and A. L. Gartel. 2006. CDK9 phosphorylates p53 on serine residues 33, 315 and 392. Cell Cycle 5:519-521.
34. Resnick, L., J. S. Herbst, D. V. Ablashi, S. Atherton, B. Frank, L. Rosen, and S. N. Horwitz. 1988. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 259:384-388.
35. Royds, J. A., M. Hibma, B. R. Dix, L. Hananeia, I. A. Russell, A. Wiles, D. Wynford-Thomas, and A. W. Braithwaite. 2006. p53 promotes adenoviral replication and increases late viral gene expression. Oncogene 25:1509-1520.
36. Schavinsky-Khrapunsky, Y., M. Huleihel, M. Aboud, and A. Torgeman. 2003. Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells. Oncogene 22:5315-5324.
37. Shadan, F. F., L. M. Cowsert, and L. P. Villarreal. 1994. n-Butyrate, a cell cycle blocker, inhibits the replication of polyomaviruses and papillomaviruses but not that of adenoviruses and herpesviruses. J. Virol. 68:4785-4796.
38. Sheu, L. F., A. Chen, H. H. Tseng, F. J. Leu, J. K. Lin, K. C. Ho, and C. L. Meng. 1995. Assessment of p53 expression in nasopharyngeal carcinoma. Hum. Pathol. 26:380-386.
39. Spruck, C. H., III, Y. C. Tsai, D. P. Huang, A. S. Yang, W. M. Rideout III, M. Gonzalez-Zulueta, P. Choi, K. W. Lo, M. C. Yu, and P. A. Jones. 1992. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res. 52:4787-4790.
40. Staib, C., J. Pesch, R. Gerwig, J. K. Gerber, U. Brehm, A. Stangl, and F. Grummt. 1996. p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Virology 219:237-246.
41. Takahashi, T., H. Suzuki, T. Hida, Y. Sekido, Y. Ariyoshi, and R. Ueda. 1991. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778.
42. Toledo, F., and G. M. Wahl. 2006. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6:909-923.
43. Torgeman, A., N. Mor-Vaknin, E. Zelin, Z. Ben-Aroya, M. Lochelt, R. M. Flugel, and M. Aboud. 2001. Sp1-p53 heterocomplex mediates activation of HTLV-1 long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology 281:10-20.
44. Wilcock, D., and D. P. Lane. 1991. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 349:429-431.
45. Zeng, Y., L. G. Zhang, Y. C. Wu, Y. S. Huang, N. Q. Huang, J. Y. Li, Y. B. Wang, M. K. Jiang, Z. Fang, and N. N. Meng. 1985. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int. J. Cancer 36:545-547.
46. Zhang, Q., D. Gutsch, and S. Kenney. 1994. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1929-1938.
47. Zhong, L., and G. S. Hayward. 1997. Assembly of complete, functionally active herpes simplex virus DNA replication compartments and recruitment of associated viral and cellular proteins in transient cotransfection assays. J. Virol. 71:3146-3160.